Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: Synergism with chemotherapy

Journal of Thoracic Oncology

Volumn 6, Issue 5, 2011, Pages 852-863

  Hoda, Mir Alireza ^a,b   Mohamed, Amir ^a,b   Ghanim, Bahil ^a   Filipits, Martin ^a,b   Hegedus, Balazs ^a   Tamura, Masaya ^a   Berta, Judit ^a,c   Kubista, Bernd ^d   Dome, Balazs ^a,c   Grusch, Michael ^a,b   Setinek, Ulrike ^e   Micksche, Michael ^a,b   Klepetko, Walter ^a   Berger, Walter ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c National Institute of Pulmonology   (Hungary)

^d UNIVERSITY OF VIENNA   (Austria)

^e OTTO WAGNER HOSPITAL   (Austria)

Author keywords

Chemotherapy; Cisplatin resistance; Mesothelioma; mTOR; Temsirolimus

Indexed keywords

CISPLATIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; TEMSIROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER TISSUE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURAL MESOTHELIOMA; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT;

EID: 79955478665     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820e1a25     Document Type: Article

References (48)

1. Carbone M, Bedrossian CW. The pathogenesis of mesothelioma. Semin Diagn Pathol 2006;23:56-60. (Pubitemid 44415397)
2. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672. (Pubitemid 29046253)
3. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603. (Pubitemid 41434638)
4. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann Surg 1996;224:288-294.
5. van Meerbeeck JP, Scherpereel A, Surmont VF, et al. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol In press.
6. Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer 2006;42:2706-2714. (Pubitemid 44584672)
7. Pass HI. Malignant pleural mesothelioma: surgical roles and novel therapies. Clin Lung Cancer 2001;3:102-117. (Pubitemid 33138775)
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644. (Pubitemid 46606305)
9. Jackman DM. Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:154-158.
10. Marshall JL, Andrews PA. Preclinical and clinical experience with cisplatin resistance. Hematol Oncol Clin North Am 1995;9:415-429.
11. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-688. (Pubitemid 44151605)
12. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008;14:1286-1290. (Pubitemid 351413905)
13. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003;2:S169-S177.
14. Bae-Jump VL, Zhou C, Boggess JF, et al. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 2009; 115:3887-3896.
15. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-759. (Pubitemid 40568794)
16. Geoerger B, Kerr K, Tang CB, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001;61:1527-1532. (Pubitemid 34292583)
17. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007;13:4261-4270. (Pubitemid 47105991)
18. Mabuchi S, Kawase C, Altomare DA, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009;15:5404-5413.
19. Ciuffreda L, Di Sanza C, Incani UC, et al. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 10:484-495.
20. Altomare DA, You H, Xiao GH, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005;24:6080-6089. (Pubitemid 43080058)
21. Barbone D, Yang TM, Morgan JR, et al. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 2008;283:13021-13030.
22. Cacciotti P, Barbone D, Porta C, et al. SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 2005;65:5256-5262. (Pubitemid 40827336)
23. Hartman ML, Esposito JM, Yeap BY, et al. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J Thorac Cardiovasc Surg 2010;139:1233-1240.
24. Wilson SM, Barbone D, Yang TM, et al. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol 2008;39:576-583.
25. Janson V, Andersson B, Behnam-Motlagh P, et al. Acquisition of cisplatin-resistance in malignant mesothelioma cells abrogates Na ,K ,2Cl(-)-cotransport activity and cisplatin-induced early membrane blebbing. Cell Physiol Biochem 2008;22:45-56.
26. Heffeter P, Jakupec MA, Korner W, et al. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol 2007;73:1873-1886. (Pubitemid 46677901)
27. Dornetshuber R, Heffeter P, Sulyok M, et al. Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin. Mol Nutr Food Res 2009;53:904-920.
28. Kubista B, Trieb K, Sevelda F, et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 2006;24:1145-1152. (Pubitemid 43870876)
29. Ismail-Khan R, Robinson LA, Williams CC Jr, et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Control 2006;13:255-263. (Pubitemid 44600936)
30. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
31. Kaufman AJ, Pass HI. Current concepts in malignant pleural mesothelioma. Expert Rev Anticancer Ther 2008;8:293-303. (Pubitemid 351385919)
32. Varghese S, Chen Z, Bartlett DL, et al. Activation of the phosphoinositide- 3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer 2011;117:361-371.
33. Schramm A, Opitz I, Thies S, et al. Prognostic significance of epithelialmesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg 2010;37:566-572.
34. Jankiewicz M, Groner B, Desrivieres S. Mammalian target of rapamycin regulates the growth of mammary epithelial cells through the inhibitor of deoxyribonucleic acid binding Id1 and their functional differentiation through Id2. Mol Endocrinol 2006;20:2369-2381. (Pubitemid 44496407)
35. Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007;178:437-451. (Pubitemid 47196152)
36. Aguilera A, Aroeira LS, Ramirez-Huesca M, et al. Effects of rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells. Int J Artif Organs 2005;28:164-169. (Pubitemid 40485216)
37. Anagnostou VK, Bepler G, Syrigos KN, et al. High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res 2009;15:4157-4164.
38. Lopez-Lago MA, Okada T, Murillo MM, et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrindependent mTORC1 signaling. Mol Cell Biol 2009;29:4235-4249.
39. Opitz I, Soltermann A, Abaecherli M, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008;33:502-506.
40. Mohiuddin I, Cao X, Ozvaran MK, et al. Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation. Ann Surg Oncol 2002;9:310-316. (Pubitemid 34298638)
41. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284. (Pubitemid 40488633)
42. Kim KU, Wilson SM, Abayasiriwardana KS, et al. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol 2005;33:541-548. (Pubitemid 41753129)
43. Wu C, Wangpaichitr M, Feun L, et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005;4:25.
44. Viniegra JG, Losa JH, Sanchez-Arevalo VJ, et al. Modulation of PI3K/ Akt pathway by E1a mediates sensitivity to cisplatin. Oncogene 2002; 21:7131-7136. (Pubitemid 35252988)
45. Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009;69:2996-3003.
46. Liu LZ, Zhou XD, Qian G, et al. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 2007;67:6325-6332. (Pubitemid 47037515)
47. Wan X, Shen N, Mendoza A, et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006;8:394-401. (Pubitemid 43830746)
48. Frost P, Shi Y, Hoang B, et al. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007;26:2255-2262. (Pubitemid 46572812)